The subsequent IMpassion131 study was expected to confirm benefit from adding atezolizumab to the more widely used paclitaxel; however, no benefit was reported either in the overall study population or in patients with PD-L1-positive cancers [26]. This evidence concerns the gene CD274 and cancer.